Cisplatin for injection

DRUG7 trials

Sponsors

EpicentRx, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Allist Pharmaceuticals, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Guangsheng Biopharmaceutical Co., Ltd

Conditions

Biliary Tract Cancers (BTC)CLDN18.2-positive Advanced Biliary Tract CancerEGFREsophageal Squamous Cell CarcinomaLocally Advanced Unresectable Esophageal Squamous CarcinomaNSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Patients With Brain MetastasisOral Mucositis

Phase 1

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Not yet recruitingNCT06136988

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Locally Advanced Unresectable Esophageal Squamous Carcinoma

Start: 2023-12-31End: 2028-04-30Target: 129Updated: 2023-11-18

Phase 2

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

CompletedNCT03515538

EpicentRx, Inc.Oral Mucositis

Start: 2018-07-12End: 2020-10-08Updated: 2024-11-04

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Not yet recruitingNCT07151872

Qilu Pharmaceutical Co., Ltd.CLDN18.2-positive Advanced Biliary Tract Cancer

Start: 2025-09-30End: 2026-10-31Target: 120Updated: 2025-09-03

Cosiporfin Sodium for Injection Photodynamic Therapy

RecruitingNCT07398339

Shanghai Guangsheng Biopharmaceutical Co., LtdBiliary Tract Cancers (BTC)

Start: 2026-03-31End: 2028-03-31Target: 30Updated: 2026-02-09

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

Not yet recruitingNCT07618910

Tang-Du HospitalEsophageal Squamous Cell Carcinoma

Start: 2026-05-30End: 2028-05-30Target: 33Updated: 2026-06-01

Phase 3

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

RecruitingNCT06956001

Allist Pharmaceuticals, Inc.EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2024-11-19End: 2028-07-01Target: 300Updated: 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

RecruitingNCT06970639

Allist Pharmaceuticals, Inc.NSCLC Patients With Brain Metastasis

Start: 2024-09-26End: 2029-09-01Target: 380Updated: 2026-02-12

Related Papers

RRx-001 potentially reduces financial toxicity for patients and caregivers in head and neck cancer.

JCO Oncology Practice2023-10-26

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.

2023-03-1528 citations

Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in patients with head and neck cancer treated with chemoradiation (PREVLAR).

Journal of Clinical Oncology2022-06-013 citations

Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).

Journal of Clinical Oncology2020-05-201 citations